By reducing insulin dosage and the associated risk of severe hypoglycemia, as well as cardiovascular and renal morbidity and mortality, these therapies could significantly improve health outcomes and reduce disability among individuals with diabetes. This evidence concerns the gene INS and diabetes mellitus.